Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Potent and safer antioxidants, and their use, claimed by Jenapharm

Nov. 17, 2000

Naeja describes preparation, activity and use of new cathepsin inhibitors

Nov. 16, 2000

NOS inhibitors derived from lipoic acid described in recent patent by SCRAS

Nov. 16, 2000

ALS treatment now available from Aventis in Canada

Nov. 16, 2000

NeoTherapeutics to focus on higher doses of Neotrofin

Nov. 16, 2000

Novel voltage-sensitive sodium channel blockers designed by CoCensys

Nov. 15, 2000

Lilly's Zyprexa approved by FDA for extended schizophrenia indication

Nov. 15, 2000

Bentley obtains license from Dartmouth for novel use of androgen therapy

Nov. 15, 2000

Neurotrophic compounds prepared by Krenitsky scientists and their use

Nov. 14, 2000

Synthesis and use of thiazolobenzimidazoles interacting with mglu receptors

Nov. 14, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 24, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
In the clinic for June 22, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...
K2 nabs two Antengene bispecific TCEs in $2B license, option deal
BioWorld
MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene...